Centessa Pharmaceuticals (CNTA) Price & Analysis

Compare

164 Followers

CNTA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$9.60 - $19.09

Previous CloseN/A

Volume658.98K

Average Volume (3M)1.04M

Market Cap

$2.29B

Enterprise Value$1.75B

Total Cash (Recent Filing)$284.50M

Total Debt (Recent Filing)$118.00M

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Aug 18, 2025

EPS Estimate

-0.33

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding133,618,770

10 Day Avg. Volume1,254,281

30 Day Avg. Volume1,040,673

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue116.43

Enterprise Value/Gross Profit119.59

Enterprise Value/Ebitda-8.41

Forecast

1Y Price Target

$32.00

Price Target Upside86.26% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Market PerceptionThe topline NT1 results from competitor ALKS are seen as encouraging for CNTA's ORX750 because they validate the orexin agonist class and suggest potential for differentiation in efficacy and/or safety.

Product DifferentiationEarly safety data suggest ORX750 may offer a convenient once-daily oral drug with a cleaner safety profile.

Bears Say

Regulatory And Clinical RisksRisks to the rating and price target include safety, clinical, regulatory, competition, and financing challenges common in development stage biotechs.

Safety ConcernsThere is a risk that visual disturbances, observed in earlier trials, might be an on-target treatment effect, which could appear in ORX750 trials since its trial design does not include ophthalmic exams.

Centessa Pharmaceuticals News

Alkermes narcolepsy trial results ‘encouraging’ for Centessa, says Leerink

After Alkermes (ALKS) issued a press release reporting top-line data for the Phase 2 Vibrance-1 trial evaluating once-daily...

18d ago

ALKS

CNTA

Centessa initiated with a Buy at Truist

Truist initiated coverage of Centessa (CNTA) with a Buy rating and $30 price target The firm sees “significant...

19d ago

CNTA

Promising Outlook for Centessa Pharmaceuticals: ORX750’s Potential Differentiation and Efficacy Drive Buy Rating

Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on...

17d ago

CNTA

Positive Market Outlook for Centessa Pharmaceuticals Driven by Promising Developments in Orexin Agonist Class

Leerink Partners analyst David Risinger has maintained their bullish stance on CNTA stock, giving a Buy rating on...

24d ago

CNTA

Optimistic Buy Rating for Centessa Pharmaceuticals Driven by Orexin Agonist Market Potential and Positive Safety Profile

Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of...

25d ago

CNTA

Centessa Pharmaceuticals Positioned for Leadership in Orexin Agonist Market with Promising ORX750 Candidate

Analyst Kostas Biliouris of BMO Capital maintained a Buy rating on Centessa Pharmaceuticals, retaining the price target of...

1M ago

CNTA

Centessa Pharmaceuticals Approves Key Resolutions at AGM

The latest announcement is out from Centessa Pharmaceuticals ( ($CNTA) ). On June 20, 2025, Centessa Pharmaceuticals held...

2M ago

CNTA

Centessa Pharmaceuticals Gains FDA Clearance for ORX142 Study

Centessa Pharmaceuticals ( ($CNTA) ) just unveiled an update. On June 16, 2025, Centessa Pharmaceuticals announced that the...

2M ago

CNTA

Centessa announces clearance of IND for ORX142

Centessa (CNTA) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has cleared the IND to initiate...

2M ago

CNTA

Centessa Pharmaceuticals: Buy Rating Affirmed on Promising Orexin Agonist Program and Innovative Trial Design

Leerink Partners analyst David Risinger has reiterated their bullish stance on CNTA stock, giving a Buy rating on...

2M ago

CNTA

Centessa Pharmaceuticals: Promising Orexin Drug Pipeline and Strong Market Potential Drive Buy Rating

Analyst Kelly Shi from Jefferies maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report) and keeping...

2M ago

CNTA

Centessa Pharmaceuticals Appoints New Chief Accounting Officer

Centessa Pharmaceuticals ( ($CNTA) ) has issued an update. On May 27, 2025, Centessa Pharmaceuticals appointed Raphael Deferiere...

2M ago

CNTA

Centessa initiated with a Buy at Needham

Needham initiated coverage of Centessa (CNTA) with a Buy rating and $35 price target Centessa’s ORX750 has a...

2M ago

CNTA

Positive Outlook on Centessa Pharmaceuticals Driven by ORX750’s Promising Potential and Market Growth

Centessa Pharmaceuticals (CNTA) has received a new Buy rating, initiated by Needham analyst, Ami Fadia. Ami Fadia’s rating...

2M ago

CNTA

CNTA FAQ

What was Centessa Pharmaceuticals Plc’s price range in the past 12 months?

Centessa Pharmaceuticals Plc lowest stock price was $9.60 and its highest was $19.09 in the past 12 months.

What is Centessa Pharmaceuticals Plc’s market cap?

Centessa Pharmaceuticals Plc’s market cap is $2.29B.

When is Centessa Pharmaceuticals Plc’s upcoming earnings report date?

Centessa Pharmaceuticals Plc’s upcoming earnings report date is Aug 18, 2025 which is in 9 days.

How were Centessa Pharmaceuticals Plc’s earnings last quarter?

Centessa Pharmaceuticals Plc released its earnings results on May 14, 2025. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.325 by $0.125.

Is Centessa Pharmaceuticals Plc overvalued?

According to Wall Street analysts Centessa Pharmaceuticals Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Centessa Pharmaceuticals Plc pay dividends?

Centessa Pharmaceuticals Plc does not currently pay dividends.

What is Centessa Pharmaceuticals Plc’s EPS estimate?

Centessa Pharmaceuticals Plc’s EPS estimate is -0.33.

How many shares outstanding does Centessa Pharmaceuticals Plc have?

Centessa Pharmaceuticals Plc has 133,618,770 shares outstanding.

What happened to Centessa Pharmaceuticals Plc’s price movement after its last earnings report?

Centessa Pharmaceuticals Plc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.325. Following the earnings report the stock price went down -1.525%.

Which hedge fund is a major shareholder of Centessa Pharmaceuticals Plc?

Currently, no hedge funds are holding shares in CNTA

Centessa Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-74.29%

Trailing 12-Months

Asset Growth

60.84%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Centessa Pharmaceuticals Plc

Centessa Pharmaceuticals is a biopharmaceutical company focused on discovering and developing innovative medicines for a wide range of diseases. The company operates in the pharmaceuticals sector, with a portfolio encompassing diverse therapeutic areas such as oncology, hematology, and rare diseases. Centessa leverages a unique 'asset-centric' research model that prioritizes the development of high-potential drug candidates through a network of subsidiary companies, each focused on distinct therapeutic areas.

Centessa Pharmaceuticals (CNTA) Earnings & Revenues

Historic Earnings Reports

CNTA Stock 12 Month Forecast

Average Price Target

$32.00

▲(86.26% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","15":"$15","23":"$23","31":"$31","39":"$39"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$27.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,15,23,31,39],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.17,15.08,16.99,18.9,20.81,22.72,24.63,26.54,28.45,30.36,32.269999999999996,34.18,36.089999999999996,{"y":38,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.17,14.618461538461538,16.066923076923075,17.515384615384615,18.963846153846152,20.412307692307692,21.86076923076923,23.309230769230766,24.757692307692306,26.206153846153846,27.654615384615383,29.10307692307692,30.551538461538456,{"y":32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13.17,14.233846153846153,15.297692307692309,16.361538461538462,17.425384615384615,18.48923076923077,19.553076923076922,20.61692307692308,21.68076923076923,22.744615384615386,23.808461538461536,24.872307692307693,25.936153846153847,{"y":27,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.48,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.8,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.29,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.67,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.75,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.92,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.55,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.23,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.41,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >